Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem‐cell transplantation. Issue 1 (21st November 2017)

• Record Type: Journal Article
• Authors: Copeland, Vanessa; McLaughlin, Milena; Trifilio, Steven
• Is Part Of: Clinical transplantation. Volume 32:Issue 1(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-11-21
• Subjects: antimicrobial prophylaxis -- fluoroquinolones -- infection -- stem‐cell transplantation; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.13145
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: The objective of the current retrospective study was to compare differences in rate of breakthrough infections for ciprofloxacin vs levofloxacin prophylaxis in autologous hematopoietic stem‐cell transplant (HSCT) patients treated for multiple myeloma. This was a retrospective, cohort study comparing autologous HSCT recipients treated for multiple myeloma who received ciprofloxacin prophylaxis vs levofloxacin prophylaxis. A total of 297 patients, 143 levofloxacin‐ and 154 ciprofloxacin‐treated were included. There was a significantly higher incidence of bloodstream infections in the ciprofloxacin group (24/154) compared to the levofloxacin group (10/143), P = .03, primarily caused by a statistically higher incidence of gram‐positive bloodstream infections (ciprofloxacin [21/154] vs levofloxacin [8/143]; P < .01). Clinically relevant differences exist between fluoroquinolone agents used for prophylaxis. Levofloxacin prophylaxis was more effective than ciprofloxacin prophylaxis to reduce the incidence of bloodstream infections in this study.